The effect of azithromycin treatment on respiratory morbidity in children with down syndrome
The significant reduction in respiratory LOS suggests the potential benefits of Azithromycin in children with DS, and emphasizes the need for larger clinical trials to determine optimal use and long-term effects in this vulnerable population.
Authors
- Guy Hazan (ORCID: https://orcid.org/0000-0002-7372-6262)
- Inbal Golan‐Tripto (ORCID: https://orcid.org/0000-0001-6259-405X)
- Noga Arwas (ORCID: https://orcid.org/0000-0003-2782-642X)
- Aviv Goldbart (ORCID: https://orcid.org/0000-0002-7063-4653)
- Itai Hazan (ORCID: https://orcid.org/0000-0002-6064-6909)
- Omer Dor
Institutions
- Ben-Gurion University of the Negev (IL)
- Soroka Medical Center (IL)
Publication Details
- Journal
- BMC Pediatrics
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1186/s12887-025-05421-1
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71